Prostate Cancer and Prostatic Diseases

Article	Citations
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer	116
Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level	91
A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk	65
Advances in PSMA-targeted therapy for prostate cancer	64
Racial disparities in prostate cancer among black men: epidemiology and outcomes	53
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches	51
Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies	49
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men	45
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors	42
Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis	41
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide	40
Quality of information and appropriateness of ChatGPT outputs for urology patients	38
3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction	36
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	36
Treating the patient and not just the cancer: therapeutic burden in prostate cancer	35
Clinical considerations for the management of androgen indifferent prostate cancer	32
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and networ	32
Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth	31
Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study	31
Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis	30
The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis	30
Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis	30
Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review	28
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients	27
The microbiome and prostate cancer	26

Robotic assisted simple prostatectomy versus other treatment modalities for large benign prostatic hyperplasia: a systematic review and meta-analysis of over 6500 cases	25
Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study	25
Disparities in germline testing among racial minorities with prostate cancer	25
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States	24
TP53 alterations of hormone-naïve prostate cancer in the Chinese population	23
Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial	23
Comparison of Retzius-sparing and conventional robot-assisted laparoscopic radical prostatectomy regarding continence and sexual function: an updated meta-analysis	23
Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study	23
The effectiveness of psychological intervention for depression, anxiety, and distress in prostate cancer: a systematic review of literature	22
Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer	21
Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency	21
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer	21
PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer	21
Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer	21
Psychological distress in men with prostate cancer undertaking androgen deprivation therapy: modifying effects of exercise from a year-long randomized controlled trial	21
Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies	21
Barriers and facilitators related to undertaking physical activities among men with prostate cancer: a scoping review	20
Clinical significance of STEAP1 extracellular vesicles in prostate cancer	20
Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes	20
Oncological outcomes of cribriform histology pattern in prostate cancer patients: a systematic review and meta-analysis	19
Artificial intelligence applications in prostate cancer	19
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer	19
Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy—implications on clinically-significant prostate cancer detection and relevance to focal therapy planning	19
Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative	19
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics	19
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis	19
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study	18
Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer	18
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score	18
A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy	18
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer	18
Statins and prostate cancer—hype or hope? The epidemiological perspective	18
What is the minimal dose for resistance exercise effectiveness in prostate cancer patients? Systematic review and meta-analysis on patient-reported outcomes	17
Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification	17
Effects of dietary omega-3 fatty acids on orthotopic prostate cancer progression, tumor associated macrophages, angiogenesis and T-cell activation—dependence on GPR120	16
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer	16
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer	16
CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis	16
Comprehensive analysis of complications after transperineal prostate biopsy without antibiotic prophylaxis: results of a multicenter trial with 30 days’ follow-up	16
Real-world use of MRI for risk stratification prior to prostate biopsy	16
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer	15
Predictive role of node-rads score in patients with prostate cancer candidates for radical prostatectomy with extended lymph node dissection: comparative analysis with validated nomograms	15
Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer	15
Clinical implications of genomic alterations in metastatic prostate cancer	15
A comparative study of PCS and PAM50 prostate cancer classification schemes	15
Prostate cancer detection: a systematic review of urinary biosensors	15
Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study	15
Patient- and tumor-level risk factors for MRI-invisible prostate cancer	15
The obesity paradox in metastatic castration-resistant prostate cancer	14
Physical activity decreases the risk of cancer reclassification in patients on active surveillance: a multicenter retrospective study	14

Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk	14
Ethnic differences in prostate-specific antigen levels in men without prostate cancer: a systematic review	14
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)	14
Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling	14
Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer—a systematic review and meta-analysis	14
Oncological and functional outcome after partial prostate HIFU ablation with Focal-One®: a prospective single-center study	14
18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review	14
Artificial intelligence for target prostate biopsy outcomes prediction the potential application of fuzzy logic	14
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England	14
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies	14
Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control	14
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids	14
Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86,490 patients	13
Single-port transvesical versus open simple prostatectomy: a perioperative comparative study	13
Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype	13
Quality of information and appropriateness of ChatGPT outputs for urology patients	13
What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study	13
Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer	13
Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT	13
Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation	13
Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men	13
Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening	13
Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia	13
ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis	13
The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction	12
Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study	12
One-year outcomes after treatment with a drug-coated balloon catheter system for lower urinary tract symptoms related to benign prostatic hyperplasia	12
Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine	12
Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population	12
Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection	12
Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2–ERG fusions	12
Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies	12
Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men	12
A systematic review and meta-analysis of artificial intelligence diagnostic accuracy in prostate cancer histology identification and grading	12
Outcomes and clinical predictors of extracorporeal shock wave therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome: a prospective randomized double-blind placebo-controlled cli	12
Characterisation of cell lines derived from prostate cancer patients with localised disease	11
Guidelines for genetic testing in prostate cancer: a scoping review	11
Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer	11
The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates	11
Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience	11
The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study	11
Gut environment changes due to androgen deprivation therapy in patients with prostate cancer	11
Urine spermine and multivariable Spermine Risk Score predict high-grade prostate cancer	11
Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?	11
High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer	11
Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer	11
Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for	11
Association between environmental quality and prostate cancer stage at diagnosis	11
Rationale and protocol for randomized study of transrectal and transperineal prostate biopsy efficacy and complications (ProBE-PC study)	11
Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis	11
Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases	11
Dietary inflammatory index and prostate cancer risk: MCC-Spain study	10
Transperineal magnetic resonance imaging targeted biopsy versus transrectal route in the detection of prostate cancer: a systematic review and meta-analysis	10
Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes	10
Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020	10
Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223	10
Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24	10
Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection	10
Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only	10
Nomograms in PCa: where do we stand	10
Racial disparities in treatment delay among younger men with prostate cancer	10
Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models	10
Instagram and prostate cancer: using validated instruments to assess the quality of information on social media	10
Modifiable risk factors for prostate cancer in low- and lower-middle-income countries: a systematic review and meta-analysis	10
Clinicogenomic characterization of prostate cancer liver metastases	10
The effect of preoperative membranous urethral length on likelihood of postoperative urinary incontinence after robot-assisted radical prostatectomy	9
From BPH to male LUTS: a 20-year journey of the EAU guidelines	9
NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer	9
Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk	9
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed	9
Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis	9
Overdiagnosis and stage migration of ISUP 2 disease due to mpMRI-targeted biopsy: facts or fictions	9
Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study	9
The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)	9
Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials	9
Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer	9
A transcriptomic model for homologous recombination deficiency in prostate cancer	9
Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis	9
Urinary microbiota and prostatic diseases: the key for the lock? A systematic review	9
Statins and prostate cancer—hype or hope? The biological perspective	9

EXIT from TRansrectal prostate biopsies (TREXIT): sepsis rates of transrectal biopsy with rectal swab culture guided antimicrobials versus freehand transperineal biopsy	9
Single port robot-assisted radical and simple prostatectomy: a systematic review and meta-analysis	9